As of today effective drugs for Alzheimer’s and Parkinson’s diseases are missing. In fact, pharma giant Pfizer recently announced that they’re ending their research in this field. Which from an innovation analytics point of view does not come as a complete surprise. In contrast, the patent strength of the Roche portfolio in Alzheimer’s and Parkinson’s patents is rising steadily.
The LexisNexis® PatentSight® Patent Asset Index trend of patents for nervous system disorder drugs reveals that the quality of Pfizer’s patents in this field has been dropping steadily since 2005. Their R&D expenditures simply did not pay off.
About Roche: the company is one of the world’s largest biotech companies and a leading provider of in-vitro diagnostics. It is a global supplier of transformative innovative solutions across major disease areas, including Alzheimer’s and Parkinson’s patents.
Effectively communicate the value of your IP with powerful insights and visualizations. This will enable you to turn your patent department into a strategic consulting unit.
With LexisNexis® Intellectual Property Solutions, you benefit from a highly transparent scientific approach to patent data analysis. Forget opaque algorithms and analytics ‘black boxes’, we can show you exactly how we reached at our insights. Patent analytics solution, PatentSight®, is built on the foundation of ground-breaking validated research, which is often cited in leading scientific publications.
Brought together in the patent value indicator, the Patent Asset Index, this objective approach to assessing patent quality and benchmarking patent portfolios has become a de facto standard in measuring portfolio strength.
LexisNexis Intellectual Property Solutions validates and quality-assures patent data by assigning patents to their accurate commercial owners and verifying their legal validity and remaining lifetime.
Superior datasets allow you to unveil valuable patent insights and see clearly who wields commercial power over the inventions that underpin promising patents.
Patent analyses conducted with PatentSight have proven to be more reliable than analyses based on unprocessed patent data.
